Investigational drug · Phase 3
Modified recombinant human C-type natriuretic peptide
Also called: BMN 111
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Achondroplasia.
Phase 3Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "Modified recombinant human C-type natriuretic peptide"
First trial start
2016
Jan 26, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Modified recombinant human C-type natriuretic peptide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Achondroplasia
Approved drugs for the same conditions: Achondroplasia · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Modified recombinant human C-type natriuretic peptide" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaPivotal-lookingRecruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT07441876 · 160 participants (planned) · Start Apr 20, 2026 · Primary completion Jun 2029
Drug: BMN 333; Vosoritide Injection [Voxzogo] · For: Achondroplasia
Sites: Oakland, California; Wilmington, Delaware; Chicago, Illinois · 28 sites in all
- A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03197766 · 121 participants · Start Dec 12, 2016 · Primary completion Oct 30, 2019
Drug: BMN 111; Placebo · For: Achondroplasia
Sites: Oakland, California; Torrance, California; Wilmington, Delaware · 24 sites in all
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaPivotal-lookingActive, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03424018 · 119 participants · Start Dec 12, 2017 · Primary completion Jun 2031
Drug: BMN 111 · For: Achondroplasia
Sites: Oakland, California; Torrance, California; Wilmington, Delaware · 24 sites in all
- Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT06455059 · 81 participants · Start Jun 17, 2024 · Primary completion Apr 23, 2026
Drug: Vosoritide; Placebo · For: Hypochondroplasia
Sites: Wilmington, Delaware; Washington D.C., District of Columbia; Chicago, Illinois · 23 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03583697 · 75 participants · Start Jun 13, 2018 · Primary completion Jan 26, 2022
Drug: BMN 111; Placebo · For: Achondroplasia
Sites: Oakland, California; Torrance, California; Wilmington, Delaware · 16 sites in all
- An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With AchondroplasiaActive, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT03989947 · 73 participants · Start Jun 12, 2019 · Primary completion May 2038
Drug: Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. · For: Achondroplasia
Sites: Oakland, California; Torrance, California; Wilmington, Delaware · 16 sites in all
- Vosoritide for Selected Genetic Causes of Short StatureActive, not recruiting
Andrew DauberAcademic, hospital or other
NCT04219007 · 56 participants · Start Aug 4, 2020 · Primary completion Aug 14, 2025
Drug: Vosoritide · For: Short Stature
Sites: Washington D.C., District of Columbia
BioMarin PharmaceuticalBioMarin (BMRN)
NCT02055157 · 35 participants · Start Jan 13, 2014 · Primary completion Oct 2, 2017
Drug: BMN 111 · For: Achondroplasia
Sites: Oakland, California; Torrance, California; Chicago, Illinois · 9 sites in all
- A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)Active, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT02724228 · 30 participants · Start Jan 26, 2016 · Primary completion Dec 2027
Drug: BMN 111 · For: Achondroplasia
Sites: Oakland, California; Torrance, California; Chicago, Illinois · 9 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT06668805 · 18 participants · Start Nov 22, 2024 · Primary completion Sep 16, 2026
Drug: Vosoritide Injection · For: Noonan Syndrome
Sites: Los Angeles, California; Orange, California; Aurora, Colorado · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Genome-wide Mendelian randomization identifies drugs associated with body height.
Xi L, Cheng R, Zhang M, et al. · Transl Pediatr 2024
- Guanylyl Cyclase-B Dependent Bone Formation in Mice is Associated with Youth, Increased Osteoblasts, and Decreased Osteoclasts.
Wagner BM, Robinson JW, Prickett TCR, et al. · Calcif Tissue Int 2022
- Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth.
Shuhaibar LC, Kaci N, Egbert JR, et al. · JCI Insight 2021
- Analogs of C-type natriuretic peptide as a potential new non-surgical treatment strategy in knee osteoarthritis.
Tufan AC · J Orthop 2019
- C-type natriuretic peptide analog treatment of craniosynostosis in a Crouzon syndrome mouse model.
Holmes G, Zhang L, Rivera J, et al. · PLoS One 2018
- Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.
Wendt DJ, Dvorak-Ewell M, Bullens S, et al. · J Pharmacol Exp Ther 2015
Also in development for Achondroplasia
- BMN 333Phase 31 trial
BioMarin · Achondroplasia
- KK8398Phase 31 trial
Kyowa Kirin Co., Ltd. · Achondroplasia
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- ABSK061Phase 22 trials
Abbisko Therapeutics Co, Ltd · HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer
- Combination of NavepegritidePhase 21 trial
Ascendis Pharma Growth Disorders A/S · Achondroplasia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BioMarin.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.